ALDX

Aldeyra Therapeutics Inc

Add to Watchlist

Advanced Chart

5.840

-0.02(-0.341%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.9114

Open

5.860

VWAP

5.80

Vol

453.35K

Mkt Cap

349.79M

Low

5.690

Amount

2.63M

EV/EBITDA(TTM)

Total Shares

59.41M

284.22M

EV/OCF(TTM)

P/S(TTM)

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

0.000

-100%

-0.177

-34.26%

-0.158

-37%

Estimates Revision

The market is revising Upward the revenue expectations for Aldeyra Therapeutics, Inc. (ALDX) for FY2025, with the revenue forecasts being adjusted by 481.95% over the past three months. During the same period, the stock price has changed by 156.14%.

Revenue Estimates for FY2025

Revise Upward

+481.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.81%

In Past 3 Month

Stock Price

Go Up

+156.14%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 9.50 USD with a low forecast of 9.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.840

Low

9.00

Averages

9.50

High

10.00

Current: 5.840

Low

9.00

Averages

9.50

High

10.00

BTIG

Thomas Shrader

Strong Buy

Maintains

$11 → $9

2025-04-07

Reason

BTIG

Thomas Shrader

Price Target

$11 → $9

2025-04-07

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-04-04

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-03-03

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-03-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aldeyra Therapeutics Inc (ALDX.O) is -167.43, compared to its 5-year average forward P/E of -12.22. For a more detailed relative valuation and DCF analysis to assess Aldeyra Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.22

Current PE

-167.43

Overvalued PE

12.09

Undervalued PE

-36.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.93

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.67

Undervalued EV/EBITDA

-7.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

20.60

Current PS

6.78

Overvalued PS

60.23

Undervalued PS

-19.04

Financials

Annual

Quarterly

FY2025Q2

YoY :

-43.53%

-10.17M

Operating Profit

FY2025Q2

YoY :

-42.03%

-9.77M

Net Income after Tax

FY2025Q2

YoY :

-42.86%

-0.16

EPS - Diluted

FY2025Q2

YoY :

-35.31%

-8.56M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

113.7K

USD

3-6

Months

4.8M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

4.4M

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

17.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

113.7K

USD

3-6

Months

4.8M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALDX News & Events

Events Timeline

2025-08-28 (ET)

2025-08-28

07:10:50

Aldeyra Granted Orphan Drug Status by EMA for ADX-2191

2025-08-19 (ET)

2025-08-19

07:10:17

FDA Awards Fast Track Designation to Aldeyra for ADX-2191

2025-07-24 (ET)

2025-07-24

07:22:22

Aldeyra receives orphan designation for ADX-2191 from EMA

News

9.0

08-28NASDAQ.COM

PinnedAldeyra's ADX-2191 Receives Orphan Drug Designation from EMA for Primary Vitreoretinal Lymphoma

9.0

08-28Newsfilter

PinnedAldeyra Therapeutics Granted Orphan Status by European Medicines Agency for ADX-2191 in Treating Primary Large B-Cell Lymphomas in Immune-Privileged Areas, Such as Primary Vitreoretinal Lymphoma